Q-omics provides the consensus-scored C14orf180 profile across patient tissues and cancer cell-line models. C14orf180 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C14orf180 is differentially expressed in 17, with the highest sampling consensus in THCA. Additionally, C14orf180 RNA expression shows 11,038 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where C14orf180 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C14orf180 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C14orf180 survival associations across molecular data types. C14orf180 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C14orf180 RNA expression–survival associations across cancer types. High C14orf180 expression shows unfavorable associations in UCEC, HNSC and LUSC, but favorable associations in KIRC, ACC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C14orf180 RNA expression.
This table summarizes C14orf180 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for C14orf180. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C14orf180 shows lower tumor expression in THCA, KICH, COAD, HNSC, LUAD and BRCA. The THCA box plot shows higher C14orf180 RNA expression in normal versus tumor tissue (log2 FC = −0.805, t-test p < 0.001).
This table shows molecular features associated with C14orf180 in patient tissues and cancer cell lines. In patient samples, C14orf180 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C14orf180 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
